Freenome (NASDAQ:FRNM) Short Interest Update

Freenome (NASDAQ:FRNM) was the target of a significant growth in short interest in August. As of August 14th, there was short interest totaling 1,416,509 shares, a growth of 217.8% from the July 30th total of 445,737 shares. Based on an average trading volume of 808,742 shares, the short-interest ratio is currently 1.8 days. Currently, 22.3% of the company’s stock are short sold.

Freenome Trading Down 0.9%

Shares of Freenome stock traded down $0.13 on Thursday, hitting $13.96. The stock had a trading volume of 226,897 shares, compared to its average volume of 831,666. The company has a market capitalization of $113.91 million, a price-to-earnings ratio of -232.66 and a beta of 0.35. Freenome has a twelve month low of $9.97 and a twelve month high of $14.34.

Analysts Set New Price Targets

Several research analysts recently commented on FRNM shares. Leerink Partners assumed coverage on Freenome in a research report on Friday, August 14th. They set an “outperform” rating and a $18.00 price target for the company. Weiss Ratings initiated coverage on Freenome in a research report on Monday. They set a “sell (d+)” rating on the stock. Jefferies Financial Group started coverage on Freenome in a research note on Monday, August 17th. They set a “buy” rating and a $17.00 price objective on the stock. TD Cowen began coverage on Freenome in a report on Tuesday, August 18th. They issued a “buy” rating and a $17.00 price objective for the company. Finally, BTIG Research began coverage on shares of Freenome in a research note on Monday, August 17th. They issued a “buy” rating and a $17.00 target price for the company. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Freenome Company Profile

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.